Exai Bio Secures $67.5 Million Series A Financing to Advance Next-Generation, RNA-Based Liquid Biopsy Platform for Early Cancer Detection

SAN FRANCISCO--(BUSINESS WIRE)-- #innovation--Exai Bio announces $67.5M Series A to advance its RNA-based liquid biopsy platform; Announces supporting data at San Antonio Breast Cancer Conference

Click to view original post